Phase 3 Lung Diseases Clinical Trials
7 recruitingPhase 3
What is a Phase 3 trial?
Phase 3 trials compare the new treatment against the current standard of care in large groups, often hundreds to thousands of participants. Successful Phase 3 results are typically required for regulatory approval.
Showing 1–7 of 7 trials
Recruiting
Phase 3
Study of Treatment With Sacituzumab and Zimberelimab for Patients With Lung Cancer Confined to the Chest and Previously Operated on Who Were Not Disease-free.
Lung Diseases
Fundación GECP129 enrolled30 locationsNCT06431633
Recruiting
Phase 3
A Study to Test Whether Nerandomilast Helps People With Lungfibrosis Related to Rheumatic Diseases
Interstitial Lung DiseasesSystemic Autoimmune Rheumatic Diseases Associated Interstitial Lung Diseases
Boehringer Ingelheim400 enrolled158 locationsNCT06806592
Recruiting
Phase 3
A Study to Test Whether Nerandomilast Can Help Slow Down Changes in the Lung in People With a Family History of Pulmonary Fibrosis
Interstitial Lung DiseasesFamilial Pulmonary FibrosisInterstitial Lung Abnormalities
Boehringer Ingelheim80 enrolled56 locationsNCT07201922
Recruiting
Phase 3
A Study of the Efficacy and Safety of Belimumab in Adults With Interstitial Lung Disease Associated With Connective Tissue Disease
Lung Diseases, Interstitial
GlaxoSmithKline440 enrolled131 locationsNCT06572384
Recruiting
Phase 2Phase 3
Anlotinib Capsules in the Treatment for IPF/PF-ILDs
Interstitial Lung Diseases
First Affiliated Hospital of Wenzhou Medical University30 enrolled1 locationNCT05828953
Recruiting
Phase 2Phase 3
Efficacy and Safety of Olokizumab in Patients With Progressive Fibrosing Interstitial Lung Diseases
Lung Diseases, Interstitial
R-Pharm International, LLC138 enrolled33 locationsNCT06440746
Recruiting
Phase 3
Evaluation of Efficacy and Safety of Rituximab in Patients With Progressive Interstitial Lung Disease (ILD) With Inflammatory Component: a Multicentre Double-blind Placebo-controlled Randomized Trial
Lung Diseases
University Hospital, Tours126 enrolled1 locationNCT05596786